



## **BD Announces Results for 2011 Fourth Fiscal Quarter and Full Year**

November 2, 2011

FRANKLIN LAKES, N.J., Nov. 2, 2011 /PRNewswire via COMTEX/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of \$2.051 billion for the fourth fiscal quarter ended September 30, 2011, representing an increase of 9.5 percent from the prior-year period, or 4.0 percent on a foreign currency-neutral basis.

For the full fiscal year ended September 30, 2011, BD reported revenues of \$7.829 billion, representing an increase of 6.2 percent over the prior year. On a foreign currency-neutral basis, revenues increased 2.9 percent, despite an unfavorable comparison to the prior year of about 2.0 percentage points due to strong sales related to the H1N1 flu pandemic, supplemental spending in Japan and stimulus spending in the U.S. in fiscal year 2010.

"We are pleased with our solid finish to fiscal year 2011. Despite a challenging business environment, all segments contributed to our success and growth," said Vincent A. Forlenza, Chief Executive Officer and President. "We will continue to drive operational efficiencies and make capital and R&D investments to support our innovation strategy as we look to fiscal year 2012 and beyond."

### **Update on the Acquisition of Carmel Pharma, AB**

As announced in August 2011, the Company completed the acquisition of Carmel Pharma, AB, a Swedish company that manufactures the BD PhaSeal(TM) System. This is the leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials. The financial impact of the acquisition on our fourth quarter results was in line with our guidance.

### **Fourth Quarter Earnings and Analysis of the Full Fiscal Year 2011 and 2010 Earnings**

Reported diluted earnings per share from continuing operations for the fourth quarter were \$1.36, compared with \$1.24 in the prior-year period, representing a 9.7 percent increase. Current quarter results included a non-cash charge of \$9 million, or \$0.03 per share from continuing operations, resulting from the discontinuance of a research program within the Diagnostic Systems unit. Excluding this item, adjusted diluted earnings per share from continuing operations increased by 12.1 percent to \$1.39, compared with \$1.24 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fourth quarter increased by 8.1 percent.

For the full fiscal year ended September 30, 2011, reported diluted earnings per share from continuing operations were \$5.59, compared with \$4.90 in the prior fiscal year, representing an increase of 14.1 percent. Excluding the aforementioned charge of \$9 million, or \$0.03 per share from continuing operations, and the 2010 fiscal year charge of \$0.04 per share from continuing operations related to healthcare reform impacting Medicare Part D reimbursements, adjusted diluted earnings per share from continuing operations increased by 13.8 percent to \$5.62, compared with \$4.94 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fiscal year increased 8.1 percent.

### **Segment Results**

In the BD Medical segment, worldwide revenues for the quarter were \$1.055 billion, representing an increase of 10.0 percent compared with the prior-year period. Revenues increased 3.8 percent on a foreign currency-neutral basis. Segment revenue growth reflected strong Diabetes Care and international safety sales, along with solid sales of Pharmaceutical Systems products. For the twelve-month period ended September 30, 2011, BD Medical revenues increased 5.6 percent, or 2.3 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$642 million, representing an increase of 8.6 percent compared with the prior-year period, or 3.8 percent on a foreign currency-neutral basis. Revenues reflected solid growth in both the Women's Health and Cancer and the Infectious Disease product offerings within the Diagnostic Systems unit. For the twelve-month period ended September 30, 2011, BD Diagnostics revenues increased 7.0 percent, or 3.9 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were \$354 million, representing an increase of 9.6 percent compared with the prior-year period. Revenues increased 4.7 percent on a foreign currency-neutral basis, primarily driven by instrument and reagent sales in the Cell Analysis unit. For the twelve-month period ended September 30, 2011, BD Biosciences revenues increased 6.7 percent, or 3.2 percent on a foreign currency-neutral basis.

### **Geographic Results**

Fourth quarter revenues in the U.S. were \$843 million, representing an increase of 1.3 percent compared with the prior-year period. Revenues outside of the U.S. were \$1.208 billion, representing an increase of 16.0 percent compared with the prior-year period, or 6.1 percent on a foreign currency-neutral basis. International revenue growth was driven by continued strength in safety sales and strong growth in emerging markets. For the twelve-month period ended September 30, 2011, revenues in the U.S. were \$3.356 billion, representing an increase of 2.1 percent compared with the prior-year period. Revenues outside of the U.S. were \$4.473 billion, representing an increase of 9.5 percent compared with the prior-year period, or 3.6 percent on a foreign currency-neutral basis.

### **Fiscal 2012 Outlook for Full Year**

The Company estimates that reported revenues for the full fiscal year 2012 will increase about 1 to 3 percent, or 2 to 4 percent on a foreign currency-neutral basis. Our guidance reflects the anticipated effects of lower healthcare utilization, reduced research funding and global macroeconomic conditions. The Company expects reported diluted earnings per share from continuing operations for fiscal year 2012 to be between \$5.75 and \$5.85. The Company also plans to repurchase, subject to market conditions, \$1.5 billion of its common stock in fiscal year 2012, and fund the repurchases through ongoing cash flow and the issuance of debt.

### **Conference Call Information**

A conference call regarding BD's fourth quarter results and its expectations for the full fiscal year 2012 will be broadcast live on BD's website, [www.bd.com/investors](http://www.bd.com/investors), along with related slides, at 8:00 a.m. (ET) Wednesday, November 2, 2011. The slides will be available concurrent with the issuance of this press release at [www.bd.com/investors](http://www.bd.com/investors). The conference call will be available for replay on BD's website, [www.bd.com/investors](http://www.bd.com/investors), or at 855-859-2056 (domestic) and 404-537-3406 (international) through the close of business on Wednesday, November 9, 2011, access code 16826583.

### **Non-GAAP Financial Measures**

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

### **About BD**

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit <http://www.bd.com/>.

This press release, including the section entitled "Fiscal 2012 Outlook", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact: Monique N. Dolecki, Investor Relations - 201-847-5453 Colleen T. White, Corporate Communications - 201-847-5369

**BECTON DICKINSON AND COMPANY**  
**CONSOLIDATED INCOME STATEMENTS**  
(Unaudited; Amounts in thousands, except per share data)

	Three Months Ended September 30,		
	2011	2010	% Change
REVENUES	\$ 2,050,795	\$ 1,873,195	9.5
Cost of products sold	999,352	900,933	10.9
Selling and administrative	487,232	438,139	11.2
Research and development	126,054	123,606	2.0
<b>TOTAL OPERATING COSTS AND EXPENSES</b>	<b>1,612,638</b>	<b>1,462,678</b>	<b>10.3</b>
OPERATING INCOME	438,157	410,517	6.7
Interest income	1,915	14,594	(86.9)
Interest expense	(22,334)	(12,278)	81.9
Other income, net	1,272	1,285	(1.0)
<b>INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES</b>	<b>419,010</b>	<b>414,118</b>	<b>1.2</b>
Income tax provision	117,606	121,065	(2.9)
<b>INCOME FROM CONTINUING OPERATIONS</b>	<b>301,404</b>	<b>293,053</b>	<b>2.8</b>
<b>(LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$81 AND \$27,645, RESPECTIVELY</b>	<b>(1,424)</b>	<b>103,642</b>	<b>NM</b>
<b>NET INCOME</b>	<b>\$ 299,980</b>	<b>\$ 396,695</b>	<b>(24.4)</b>

## EARNINGS PER SHARE

Basic:					
Income from continuing operations	\$	1.39	\$	1.27	9.4
(Loss) Income from discontinued operations	\$	(0.01)	\$	0.45	NM
Net income (1)	\$	1.38	\$	1.71	(19.3)
Diluted:					
Income from continuing operations	\$	1.36	\$	1.24	9.7
(Loss) Income from discontinued operations	\$	(0.01)	\$	0.44	NM
Net income (1)	\$	1.36	\$	1.68	(19.0)

## AVERAGE SHARES OUTSTANDING

Basic	216,726	231,396
Diluted	220,859	236,316

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

Page 1

## BECTON DICKINSON AND COMPANY CONSOLIDATED INCOME STATEMENTS (Unaudited; Amounts in thousands, except per share data)

	Twelve Months Ended September 30,		
	2011	2010	% Change
REVENUES	\$ 7,828,904	\$ 7,372,333	6.2
Cost of products sold	3,737,352	3,543,183	5.5
Selling and administrative	1,851,774	1,721,356	7.6
Research and development	476,496	430,997	10.6
TOTAL OPERATING COSTS AND EXPENSES	6,065,622	5,695,536	6.5
OPERATING INCOME	1,763,282	1,676,797	5.2
Interest income	43,209	35,129	23.0
Interest expense	(84,019)	(51,263)	63.9
Other (expense) income, net	(6,209)	497	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	1,716,263	1,661,160	3.3
Income tax provision	451,411	484,820	(6.9)
INCOME FROM CONTINUING OPERATIONS	1,264,852	1,176,340	7.5
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$792 AND \$40,703, RESPECTIVELY	6,142	141,270	NM
NET INCOME	\$ 1,270,994	\$ 1,317,610	(3.5)

## EARNINGS PER SHARE

Basic:					
Income from continuing operations	\$	5.72	\$	5.02	13.9
Income from discontinued operations	\$	0.03	\$	0.60	(95.0)
Net income	\$	5.75	\$	5.62	2.3
Diluted:					
Income from continuing operations	\$	5.59	\$	4.90	14.1
Income from discontinued operations	\$	0.03	\$	0.59	(94.9)
Net income	\$	5.62	\$	5.49	2.4

## AVERAGE SHARES OUTSTANDING

Basic	221,175	234,328
Diluted	226,280	240,136

NM - Not Meaningful

Page 2

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

Three Months Ended September 30,  
2011      2010      % Change

**BD MEDICAL**

United States	\$ 404,301	\$ 400,231	1.0
International	650,290	558,374	16.5
<b>TOTAL</b>	<b>\$ 1,054,591</b>	<b>\$ 958,605</b>	<b>10.0</b>

**BD DIAGNOSTICS**

United States	\$ 313,603	\$ 307,721	1.9
International	328,445	283,743	15.8
<b>TOTAL</b>	<b>\$ 642,048</b>	<b>\$ 591,464</b>	<b>8.6</b>

**BD BIOSCIENCES**

United States	\$ 124,619	\$ 124,009	0.5
International	229,537	199,117	15.3
<b>TOTAL</b>	<b>\$ 354,156</b>	<b>\$ 323,126</b>	<b>9.6</b>

**TOTAL REVENUES**

United States	\$ 842,523	\$ 831,961	1.3
International	1,208,272	1,041,234	16.0
<b>TOTAL</b>	<b>\$ 2,050,795</b>	<b>\$ 1,873,195</b>	<b>9.5</b>

Page 3

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

Twelve Months Ended September 30,  
2011      2010      % Change

**BD MEDICAL**

United States	\$ 1,625,044	\$ 1,596,336	1.8
International	2,382,260	2,200,096	8.3
<b>TOTAL</b>	<b>\$ 4,007,304</b>	<b>\$ 3,796,432</b>	<b>5.6</b>

**BD DIAGNOSTICS**

United States	\$ 1,245,872	\$ 1,214,288	2.6
International	1,234,605	1,104,591	11.8
<b>TOTAL</b>	<b>\$ 2,480,477</b>	<b>\$ 2,318,879</b>	<b>7.0</b>

**BD BIOSCIENCES**

United States	\$ 484,853	\$ 475,941	1.9
International	856,270	781,081	9.6
<b>TOTAL</b>	<b>\$ 1,341,123</b>	<b>\$ 1,257,022</b>	<b>6.7</b>

**TOTAL REVENUES**

United States	\$ 3,355,769	\$ 3,286,565	2.1
International	4,473,135	4,085,768	9.5
<b>TOTAL</b>	<b>\$ 7,828,904</b>	<b>\$ 7,372,333</b>	<b>6.2</b>

Page 4

SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended September 30,  
(Unaudited; Amounts in thousands)

	United States		
	2011	2010	% Change
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$ 246,746	\$ 256,290	(3.7)
Diabetes Care	104,819	98,633	6.3
Pharmaceutical Systems	52,736	45,308	16.4
<b>TOTAL</b>	<b>\$ 404,301</b>	<b>\$ 400,231</b>	<b>1.0</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$ 161,556	\$ 162,024	(0.3)
Diagnostic Systems	152,047	145,697	4.4
<b>TOTAL</b>	<b>\$ 313,603</b>	<b>\$ 307,721</b>	<b>1.9</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 89,899	\$ 86,765	3.6
Discovery Labware	34,720	37,244	(6.8)
<b>TOTAL</b>	<b>\$ 124,619</b>	<b>\$ 124,009</b>	<b>0.5</b>
<b>TOTAL UNITED STATES</b>	<b>\$ 842,523</b>	<b>\$ 831,961</b>	<b>1.3</b>

Page 5

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended September 30, (continued)  
(Unaudited; Amounts in thousands)

	International					
	2011	2010	% Change			
			Reported	FXN	FX Impact	
<b>BD MEDICAL</b>						
Medical Surgical Systems	\$ 288,653	\$ 245,724	17.5	7.8	9.7	
Diabetes Care	119,832	100,468	19.3	7.6	11.7	
Pharmaceutical Systems	241,805	212,182	14.0	2.5	11.5	
<b>TOTAL</b>	<b>\$ 650,290</b>	<b>\$ 558,374</b>	<b>16.5</b>	<b>5.8</b>	<b>10.7</b>	
<b>BD DIAGNOSTICS</b>						
Preanalytical Systems	\$ 167,044	\$ 144,421	15.7	5.7	10.0	
Diagnostic Systems	161,401	139,322	15.8	6.2	9.6	
<b>TOTAL</b>	<b>\$ 328,445</b>	<b>\$ 283,743</b>	<b>15.8</b>	<b>5.9</b>	<b>9.9</b>	
<b>BD BIOSCIENCES</b>						
Cell Analysis	\$ 183,259	\$ 160,230	14.4	6.8	7.6	
Discovery Labware	46,278	38,887	19.0	9.5	9.5	
<b>TOTAL</b>	<b>\$ 229,537</b>	<b>\$ 199,117</b>	<b>15.3</b>	<b>7.3</b>	<b>8.0</b>	
<b>TOTAL INTERNATIONAL</b>	<b>\$ 1,208,272</b>	<b>\$ 1,041,234</b>	<b>16.0</b>	<b>6.1</b>	<b>9.9</b>	

Page 6

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended September 30, (continued)  
(Unaudited; Amounts in thousands)

	Total		
	2011	2010	% Change
			Reported
			FXN
			FX Impact

<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 535,399	\$ 502,014	6.7	1.9	4.8
Diabetes Care	224,651	199,101	12.8	7.0	5.8
Pharmaceutical Systems	294,541	257,490	14.4	4.9	9.5
<b>TOTAL</b>	<b>\$ 1,054,591</b>	<b>\$ 958,605</b>	<b>10.0</b>	<b>3.8</b>	<b>6.2</b>

<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 328,600	\$ 306,445	7.2	2.5	4.7
Diagnostic Systems	313,448	285,019	10.0	5.2	4.8
<b>TOTAL</b>	<b>\$ 642,048</b>	<b>\$ 591,464</b>	<b>8.6</b>	<b>3.8</b>	<b>4.8</b>

<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 273,158	\$ 246,995	10.6	5.7	4.9
Discovery Labware	80,998	76,131	6.4	1.6	4.8
<b>TOTAL</b>	<b>\$ 354,156</b>	<b>\$ 323,126</b>	<b>9.6</b>	<b>4.7</b>	<b>4.9</b>

<b>TOTAL REVENUES</b>	<b>\$ 2,050,795</b>	<b>\$ 1,873,195</b>	<b>9.5</b>	<b>4.0</b>	<b>5.5</b>
-----------------------	---------------------	---------------------	------------	------------	------------

Page 7

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Twelve Months Ended September 30,  
(Unaudited; Amounts in thousands)

	<u>United States</u>		
	2011	2010	% Change

<b>BD MEDICAL</b>			
Medical Surgical Systems	\$ 980,326	\$ 1,007,322	(2.7)
Diabetes Care	400,809	383,783	4.4
Pharmaceutical Systems	243,909	205,231	18.8
<b>TOTAL</b>	<b>\$ 1,625,044</b>	<b>\$ 1,596,336</b>	<b>1.8</b>

<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$ 643,180	\$ 627,421	2.5
Diagnostic Systems	602,692	586,867	2.7
<b>TOTAL</b>	<b>\$ 1,245,872</b>	<b>\$ 1,214,288</b>	<b>2.6</b>

<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 342,322	\$ 326,916	4.7
Discovery Labware	142,531	149,025	(4.4)
<b>TOTAL</b>	<b>\$ 484,853</b>	<b>\$ 475,941</b>	<b>1.9</b>

<b>TOTAL UNITED STATES</b>	<b>\$ 3,355,769</b>	<b>\$ 3,286,565</b>	<b>2.1</b>
----------------------------	---------------------	---------------------	------------

Page 8

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Twelve Months Ended September 30, (continued)  
(Unaudited; Amounts in thousands)

	<u>International</u>			
	2011	2010	<u>% Change</u>	
			Reported	FXN FX Impact

<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 1,101,407	\$ 1,002,687	9.8	3.5	6.3
Diabetes Care	465,668	401,976	15.8	9.1	6.7
Pharmaceutical Systems	815,185	795,433	2.5	(1.9)	4.4
<b>TOTAL</b>	<b>\$ 2,382,260</b>	<b>\$ 2,200,096</b>	<b>8.3</b>	<b>2.6</b>	<b>5.7</b>

<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 634,613	\$ 570,386	11.3	4.9	6.4
Diagnostic Systems	599,992	534,205	12.3	5.8	6.5

TOTAL	\$ 1,234,605	\$ 1,104,591	11.8	5.4	6.4
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 682,123	\$ 624,322	9.3	4.0	5.3
Discovery Labware	174,147	156,759	11.1	4.1	7.0
TOTAL	\$ 856,270	\$ 781,081	9.6	4.0	5.6
TOTAL INTERNATIONAL	\$ 4,473,135	\$ 4,085,768	9.5	3.6	5.9

Page 9

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Twelve Months Ended September 30, (continued)  
(Unaudited; Amounts in thousands)

	Total		% Change		
	2011	2010	Reported	FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 2,081,733	\$ 2,010,009	3.6	0.4	3.2
Diabetes Care	866,477	785,759	10.3	6.8	3.5
Pharmaceutical Systems	1,059,094	1,000,664	5.8	2.4	3.4
TOTAL	\$ 4,007,304	\$ 3,796,432	5.6	2.3	3.3
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 1,277,793	\$ 1,197,807	6.7	3.7	3.0
Diagnostic Systems	1,202,684	1,121,072	7.3	4.2	3.1
TOTAL	\$ 2,480,477	\$ 2,318,879	7.0	3.9	3.1
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 1,024,445	\$ 951,238	7.7	4.3	3.4
Discovery Labware	316,678	305,784	3.6	-	3.6
TOTAL	\$ 1,341,123	\$ 1,257,022	6.7	3.2	3.5
TOTAL REVENUES	\$ 7,828,904	\$ 7,372,333	6.2	2.9	3.3

Page 10

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
SAFETY REVENUES  
(Unaudited; Amounts in thousands)

	Three Months Ended September 30,		% Change		
	2011	2010	Reported	FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$ 288,541	\$ 282,968	2.0	2.0	-
International	209,209	160,396	30.4	18.5	11.9
TOTAL	\$ 497,750	\$ 443,364	12.3	7.9	4.4
<b>BY SEGMENT</b>					
BD Medical	\$ 243,521	\$ 208,822	16.6	12.4	4.2
BD Diagnostics	254,229	234,542	8.4	4.0	4.4
TOTAL	\$ 497,750	\$ 443,364	12.3	7.9	4.4

	Twelve Months Ended September 30,		% Change		
	2011	2010	Reported	FXN	FX Impact

**TOTAL SAFETY REVENUES**

United States	\$ 1,116,543	\$ 1,108,431	0.7	0.7	-
International	754,739	621,913	21.4	13.6	7.8
<b>TOTAL</b>	<b>\$ 1,871,282</b>	<b>\$ 1,730,344</b>	<b>8.1</b>	<b>5.4</b>	<b>2.7</b>

**BY SEGMENT**

BD Medical	\$ 885,156	\$ 819,084	8.1	5.4	2.7
BD Diagnostics	986,126	911,260	8.2	5.3	2.9
<b>TOTAL</b>	<b>\$ 1,871,282</b>	<b>\$ 1,730,344</b>	<b>8.1</b>	<b>5.4</b>	<b>2.7</b>

Page 11

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
FY2011 Quarter-to-Date Reconciliation  
(Unaudited; Amounts in millions, except per share data)

Three Months Ended September 30,					
	Reported FY 2011	Impairment Charge (1)	Adjusted FY 2011	Reported FY 2010	Adjusted % Growth

Diluted Earnings per Share from Continuing Operations	\$ 1.36	\$ 0.03	\$ 1.39	\$ 1.24	12.1%
--	---------	---------	---------	---------	-------

(1) Represents a non-cash impairment charge resulting from the discontinuance of a research program within the Diagnostic Systems unit.

All figures rounded. Totals may not add due to rounding.

Page 12

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
FY2011 Year-to-Date Reconciliation  
(Unaudited; Amounts in millions, except per share data)

Twelve Months Ended September 30,							
	Reported FY 2011	Impairment Charge (1)	Adjusted FY 2011	Reported FY 2010	Adjusted Tax (2)	Adjusted FY 2010	Adjusted % Growth

Diluted Earnings per Share from Continuing Operations	\$ 5.59	\$ 0.03	\$ 5.62	\$ 4.90	\$ 0.04	\$ 4.94	13.8%
--	---------	---------	---------	---------	---------	---------	-------

(1) Represents a non-cash impairment charge resulting from the discontinuance of a research program within the Diagnostic Systems unit.

(2) Represents a non-cash charge related to healthcare reform impacting Medicare Part D reimbursements.

All figures rounded. Totals may not add due to rounding.

Page 13

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
Quarter-to-Date Fiscal 2011 Reconciliation - FX Impact  
(Unaudited; Amounts in millions, except per share data)

Three Months Ended September 30,								
	Adjusted FY 2011	Reported FY 2010	Adjusted Growth \$	Foreign Currency Translation	FY10 Hedge Gain	Total FX	Adjusted FXN Change	FXN Growth

REVENUES	\$ 2,051	\$ 1,873	\$ 178	\$ 115	\$ (11)	\$ 103	\$ 74	4.0%
----------	----------	----------	--------	--------	---------	--------	-------	------

Diluted Earnings per Share from Continuing Operations	\$ 1.39	\$ 1.24	\$ 0.15	\$ 0.08	\$ (0.03)	\$ 0.05	\$ 0.10	8.1%
--	---------	---------	---------	---------	-----------	---------	---------	------



All figures rounded. Totals may not add due to rounding.  
FXN = Foreign Currency Neutral

Page 14

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
Year-to-Date Fiscal 2011 Reconciliation - FX Impact  
(Unaudited; Amounts in millions, except per share data)

	Twelve Months Ended September 30,							
	Adjusted FY 2011	Adjusted FY 2010	Adjusted Growth \$	Foreign Currency Translation	FY10 Hedge Loss	Total FX	Adjusted FXN Change	FXN Growth
REVENUES	\$ 7,829	\$ 7,372	\$ 457	\$ 208	\$ 31	\$ 240	\$ 217	2.9%
Diluted Earnings per Share from Continuing Operations	\$ 5.62	\$ 4.94	\$ 0.68	\$ 0.20	\$ 0.08	\$ 0.28	\$ 0.40	8.1%

All figures rounded. Totals may not add due to rounding.  
FXN = Foreign Currency Neutral

Page 15

SOURCE BD (Becton, Dickinson and Company)